/PRNewswire/ UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious.
Late-breaking presentation of data from the OSIRIS IIT PoC study of oral orismilast in hidradenitis suppurativa (HS) at the European Academy of Dermatology and.
Study demonstrates clinically relevant improvements in patients with hidradenitis suppurativa (HS) receiving 16 weeks of treatment with oral orismilast Study.
/PRNewswire/ UNION therapeutics A/S (UNION), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and.